Supernus, Inc.
SUPN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001625297
In the last 90 days, Supernus, Inc. insiders filed 1 open-market purchase and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesINDV
Key figures
- Market capClose on Nov 11, 2026
- $3.48B
- Insider buysLast 90 days, $53.5K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $1.24B
- +4.3% year over year
- Net income, FY2025
- $210.0M
- +10,400.0% year over year
- Free cash flow, FY2025
- -$93.0M
- −1,428.6% year over year
- Revenue, Q3 FY2026
- $356.0M
- +13.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.62M
- Shares sold short
- Change
- +575.8K
- +14.2% vs. previous
- Days to cover
- 3.42
- At average daily volume
Superinvestors holding SUPN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding SUPN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Supernus, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 27, 2026 (view filing)4:00 PM ET | Aug 27 | Same day | Anderson Woodrow DChief Accounting Officer | PPurchase | +1.50K | $35.69 | +$53.5K | +5.7%27.6K after | |
| Aug 5, 2026 (view filing)4:52 PM ET | Aug 5 | Same day | Anderson Woodrow DChief Accounting Officer | PPurchase | +1.50K | $36.28 | +$54.4K | +6.1%26.1K after | |
| Jul 13, 2026 (view filing)4:31 PM ET | Jul 10 | 3 days | Heidbreder ChristianChief Scientific Officer | SSale | −18.6K | $41.14 | −$764.6K | −8.2%209.3K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 11 | 1 day | Heidbreder ChristianChief Scientific Officer | SSale | −18.6K | $38.06 | −$707.4K | −7.5%227.9K after | 10b5-1 |
| Jun 10, 2026 (view filing) | Jun 8 | 2 days | Preblick RyanChief Financial Officer | SSale | −36.0K | $37.70 | −$1.36M | −11.2%284.8K after | 10b5-1 |
| Mar 13, 2026 (view filing) | Mar 13 | Same day | Ryan BarbaraDirector | PPurchase | +8 | $31.09 | +$248.72 | +0.1%5.72K after | |
| Mar 11, 2026 (view filing) | Mar 9 | 2 days | Ryan BarbaraDirector | PPurchase | +31 | $32.56 | +$1.01K | +0.5%5.72K after | |
| Mar 11, 2026 (view filing) | Mar 6 | 5 daysLate | Kingsley Stuart ADirector | PPurchase | +940 | $31.87 | +$30.0K | +20.2%5.58K after | |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Humphreys KeithDirector | PPurchase | +775 | $35.39 | +$27.4K | +15.4%5.80K after | 10b5-1 |
| Jan 7, 2026 (view filing) | Jan 5 | 2 days | Ryan BarbaraDirector | PPurchase | +775 | $35.39 | +$27.4K | +65.2%1.96K after | 10b5-1 |
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Supernus, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding SUPN in 13F filings for Q2 2026.